Miki Koroku 1, Teppei Omori 1, Harutaka Kambayashi 1, Shun Murasugi 1, Tomoko Kuriyama 1, Yuichi Ikarashi 1, Maria Yonezawa 1, Ken Arimura 2, Kazunori Karasawa 3, Norio Hanafusa 4, Masatoshi Kawana 5, Katsutoshi Tokushige 1 Intest Res. 2021 Mar 12. doi: 10.5217/ir.2020.00148.
Tag: Covid-19
Scientific corner
Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19
In conclusion, our patient’s case indicates that GMA for a patient with both active UC and COVID-19 is a safe treatment option for active UC that could lead other patients in this condition to remission.
Scientific corner
Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19
Koroku, Miki & Omori, Teppei & Kambayashi, Harutaka & Murasugi, Shun & Kuriyama, Tomoko & Ikarashi, Yuichi & Yonezawa, Maria & Arimura, Ken & Karasawa, Kazunori & Hanafusa, Norio & Kawana, Masatoshi & Tokushige, Katsutoshi.
Intestinal Research. 2021 DOI:10.5217/ir.2020.00148.
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.
Scientific corner
Adsorptive granulocyte and monocyte apheresis: A potentially relevant therapeutic option for COVID-19
Takuro Kanekura 1, Koichi Kawahara 2 , Int J Infect Dis 2020 Oct;99:1-2.
To our knowledge, GMA has a good safety profile; serious adverse effects are rarely reported. Its modes of action together with the findings of this case report support our notion that GMA is a relevant therapeutic option for patients with COVID-19 and warrants an immediate clinical trial to evaluate its full therapeutic efficacy in a large cohort of COVID-19 patients.
Contact UsFor more information
Contact Us